APA

Rovati L. C., Brambilla N., Blicharski T., Connell J., Vitalini C., Bonazzi A., Giacovelli G., Girolami F. & D'Amato M. (20210205). Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. : Osteoarthritis and cartilage.

Chicago

Rovati L C, Brambilla N, Blicharski T, Connell J, Vitalini C, Bonazzi A, Giacovelli G, Girolami F and D'Amato M. 20210205. Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. : Osteoarthritis and cartilage.

Harvard

Rovati L. C., Brambilla N., Blicharski T., Connell J., Vitalini C., Bonazzi A., Giacovelli G., Girolami F. and D'Amato M. (20210205). Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. : Osteoarthritis and cartilage.

MLA

Rovati L C, Brambilla N, Blicharski T, Connell J, Vitalini C, Bonazzi A, Giacovelli G, Girolami F and D'Amato M. Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. : Osteoarthritis and cartilage. 20210205.